• 1
    Tattersall MH, Sodergren JE, Dengupta SK, Trites DH, Modest EJ & Frei E III (1975) Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 17, 701708.
  • 2
    Estlin EJ & Veal GJ (2003) Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 29, 253273.
  • 3
    Sobell HM (1985) Actinomycin and DNA transcription. Proc Natl Acad Sci USA 82, 53285331.
  • 4
    Xu H & Krystal GW (2010) Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res 16, 43924400.
  • 5
    Olberding KE, Wang X, Zhu Y, Pan J, Rai SN & Li C (2010) Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Cancer Biol Ther 10, 918929.
  • 6
    Cervantes-Gomez F, Nimmanapalli R & Gandhi V (2009) Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. Cancer Res 69, 39473954.
  • 7
    Choong ML, Yang H, Lee MA & Lane DP (2009) Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 8, 28102818.
  • 8
    Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M et al. (2012) Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia 26, 25082516.
  • 9
    Gibert B, Eckel B, Fasquelle L, Moulin M, Bouhallier F, Gonin V, Mellier G, Simon S, Kretz-Remy C, Arrigo AP et al. (2012) Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins. PLoS One 7, e29719.
  • 10
    Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C & Gleave M (2006) Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 98, 10821089.
  • 11
    Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP & Solary E (1999) HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13, 20612070.
  • 12
    Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E et al. (2000) Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2, 645652.
  • 13
    Mehlen P, Kretz-Remy C, Preville X & Arrigo AP (1996) Human hsp27, Drosophila hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha-induced cell death. EMBO J 15, 26952706.
  • 14
    Arrigo AP, Virot S, Chaufour S, Firdaus W, Kretz-Remy C & Diaz-Latoud C (2005) Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal 7, 414422.
  • 15
    Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR & Klein JB (2003) Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278, 2782827835.
  • 16
    Donaldson SS, Gordon LF & Hahn GM (1978) Protective effect of hyperthermia against the cytotoxicity of actinomycin D on Chinese hamster cells. Cancer Treat Rep 62, 14891495.
  • 17
    Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ & McGuire WL (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52, 36483654.
  • 18
    Huot J, Roy G, Lambert H, Chretien P & Landry J (1991) Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 51, 52455252.
  • 19
    Vargas-Roig LM, Gago FE, Tello O, Aznar JC & Ciocca DR (1998) Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79, 468475.
  • 20
    Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E & Kroemer G (2006) Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5, 25922601.
  • 21
    Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM et al. (2012) Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 109, 86998704.
  • 22
    Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo AP, Clezardin P & Diaz-Latoud C (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 107, 6370.
  • 23
    O'Callaghan-Sunol C, Gabai VL & Sherman MY (2007) Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 67, 1177911788.
  • 24
    Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C & Gleave M (2005) Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65, 1108311093.
  • 25
    Modok S, Mellor HR & Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6, 350354.
  • 26
    Wang CY, Cusack JC Jr, Liu R & Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5, 412417.
  • 27
    Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55, 11511191.
  • 28
    Lindquist S & Craig EA (1988) The heat-shock proteins. Annu Rev Genet 22, 631677.
  • 29
    Richards EH, Hickey E, Weber L & Master JR (1996) Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56, 24462451.
  • 30
    Concannon CG, Orrenius S & Samali A (2001) Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 9, 195201.
  • 31
    Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S & Arrigo AP (2002) Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 22, 816834.
  • 32
    Ciocca DR & Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10, 86103.
  • 33
    Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG & Yoo BC (2008) Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 8, 286.
  • 34
    Calderwood SK, Khaleque MA, Sawyer DB & Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31, 164172.
  • 35
    Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T & Anderson KC (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63, 61746177.
  • 36
    Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K & Gleave M (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64, 65956602.
  • 37
    Concannon CG, Gorman AM & Samali A (2003) On the role of Hsp27 in regulating apoptosis. Apoptosis 8, 6170.
  • 38
    Sun Y, Zhou M, Fu D, Xu B, Fang T, Ma Y, Chen J & Zhang J (2011) Ubiquitination of heat shock protein 27 is mediated by its interaction with Smad ubiquitination regulatory factor 2 in A549 cells. Exp Lung Res 37, 568573.
  • 39
    Voss OH, Batra S, Kolattukudy SJ, Gonzalez-Mejia ME, Smith JB & Doseff AI (2007) Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J Biol Chem 282, 2508825099.